^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug Class: | CD20 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma...CLL/SLL without del(17p)/TP53 mutation...First-line therapy…Other recommended regimens…Bendamustine (70 mg/m2 in cycle 1 with escalation to 90 mg/m2 if tolerated) + anti-CD20 monoclonal antibody (not recommended for frail patients).
Secondary therapy:
bendamustine
